About the Enrollment Form: each semester, all students are required to complete the Enrollment Form to verify their presence on campus and make changes to their personal and directory information, if ...

Janssen's Stelara will then be the market leading product, and Lilly, Novartis and Janssen itself have all released new data showing their next generation treatments can outperform both ...

Stelara can be used to treat patients who have failed to respond to or can’t tolerate other biologic therapies for UC. J&J’s pharma unit Janssen said Stelara is the first interleukin-12/23 ...

Stelara (ustekinumab) is a brand-name injectable drug prescribed for certain autoimmune conditions. Stelara has interactions with some other drugs and certain vaccines. Examples include Orencia ...

JAMP launched JAMTEKI, its ustekinumab biosimilar of STELARA, on March 1, 2024. Janssen launched its second branded ustekinumab product, FINLIUS, on July 2, 2024. JAMP commenced its application ...

Stelara (ustekinumab) is a prescription drug that treats autoimmune conditions such as plaque psoriasis. You typically inject it subcutaneously (under your skin) or receive it intravenously ...

For the best experience in completing this form use a non-mobile device.

Vigorous protection of Stelara’s position aligns with a strategy to grow in the immunology space. Credit: josefkubes via Shutterstock. During its presentation at the JP Morgan Healthcare Conference ...

Morgan State University has formed a task force to address the decline in Black male enrollment. The group will explore the root causes behind the decline in enrollment and retention of Black men ...

Will the Stelara biosimilars be a reprise of the Humira biosimilars in 2023 and be slow to catch on? Biosimilar watchers circled 2023 as a red-letter year because that was the year that the Humira ...

While speaking at the conference, J&J’s CEO, Joaquin Duato, indicated the company’s willingness to protect Stelara, its branded anti-interleukin (IL)-12/23 biologic, against sales erosion from ...

Overall, global Stelara sales dropped 14.7% year-over-year to roughly $2.3 billion in 2024’s fourth quarter. For the full 12-month earnings period, Stelara sales slipped around 4.6% to $10.4 ...